कृपया अन्य खोज का प्रयास करें
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Maina Bhaman | 52 | 2019 | Independent Director |
John F. Thero | 63 | 2021 | Independent Director |
Marc M. P. de Garidel | 66 | 2021 | CEO & Director |
Patrick Rossignol | - | - | Member of the Scientific Advisory Board |
Morris Brown | - | - | Member of Scientific Advisory Board |
Bryan Williams | - | - | Member of the Scientific Advisory Board |
Jason Pitts | 37 | 2021 | Independent Director |
Philip T. Sager | 68 | - | Member of Scientific Advisory Board |
Suzanne Oparil | 83 | - | Member of Scientific Advisory Board |
Ulrich Granzer | 64 | - | Member of Scientific Advisory Board |
Johannes Jacob Pieter Kastelein | 70 | - | Member of the Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है